Arvinas licenses ARV-766 to Novartis for $150M upfront; up to $1.01B in milestones

ARVINAS, INC.

Arvinas grants Novartis exclusive worldwide license to develop and commercialize ARV-766 for prostate cancer.
Novartis pays $150M upfront; Arvinas eligible for up to $1.01B in development, regulatory, and commercial milestones plus tiered royalties.
Asset purchase includes Arvinas' preclinical AR-V7 program sold to Novartis.
Novartis assumes full responsibility for global clinical development and commercialization of ARV-766.
Closing subject to HSR antitrust waiting period expiration or termination.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ARVINAS, INC. entered into License Agreement with Novartis Pharma AG valued at $150.0 million upfront, up to $1.01 billion in milestones (effective 2024-04-10).

Action: entry
Agreement: license
Counterparty: Novartis Pharma AG
Value: $150.0 million upfront, up to $1.01 billion in milestones
Effective: 2024-04-10

Exact text from the filing

On April 10, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), entered into a transaction (the “Transaction”), including both a license agreement (the “License Agreement”) and an asset purchase agreement (the “Asset Agreement”), with Novartis Pharma AG (“Novartis”).

View on SEC.gov

Browse all material agreements →

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001655759-24-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.